Congress Abstracts

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Rectum, STS

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

2018 – OncoRad – NBXTR3 Abscopal Effect

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Recent results of a phase II/III in locally advanced Soft Tissue Sarcoma patients demonstrated clinical benefits of intratumorally injected HfO2-NP activated by radiotherapy compared to radiotherapy alone, validating their first-in-class mode of action. In addition, animal studies have reported that HfO2-NP+RT can induce an abscopal effect, where RT alone cannot. […]

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Recent studies reported that radiotherapy could activate the cGAS-STING pathway, which plays a fundamental role in the immune response to cytoplasmic DNA, by activation of the transcriptional factor IRF3, leading to expression of interferon-beta. Moreover, cGAS-STING activation appears to be an important component for tumor resident Antigen-Presenting Cells activation, a crucial step for induction of CD8+ T cell response against tumor derived antigens. […]

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Rectum, STS

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

Clinical Data NBTXR3, Congress Abstracts, STS

The enclosed abstract was presented at the “2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii”. The abstract “NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma” describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

2017 – Abstract SITC Conference Maryland – Clinical

Clinical Data NBTXR3, Congress Abstracts, STS

Soft tissue sarcoma (STS) is a large and heterogeneous group of malignant mesenchymal neoplasms characterized by a strong tendency toward local recurrence and metastatic spreading. Consistently, the immune microenvironment in sarcomas is highly variable. A new class of material with high electron density, hafnium oxide, was designed at the nanoscale to efficiently absorb ionizing radiation […]

Congresses are a key element for Nanobiotix to publish scientific data and results. This section lists abstracts that have been published by Nanobiotix over the last decade.